Findings of phase III trials of the Bruton's tyrosine kinase inhibitor evobrutinib in patients with relapsing multiple sclerosis were recently presented at the ACTRIMS Forum.Heather WoodNature Reviews NeurologyNature Publishing Group UKNature Reviews Neurology...
Finally, Dr Coyle examines the efficacy of the Bruton tyrosine kinase (BTK) inhibitor tolebrutinib, as evidenced by the HERCULES trial and the two GEMINI trials. In HERCULES, the BTK inhibitor reduced 6-month disability progression by a significant 31% compared with placebo. -- Patricia K....
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Sanofi’s BTK inhibitor candidate tolebrutinib for the treatment of adults with nonrelapsing secondary progressive multiple sclerosis (SPMS). According to Sanofi, tolebrutinib is the first investigational BTK...
The multiple sclerosis condition center is a resource for clinical news on the diagnosis, treatment, and management of multiple sclerosis. | NeurologyLive.
Microglia in multiple sclerosis—pathogenesis and imaging. Curr Opin Neurol. 2022;35:299–306. CAS PubMed Google Scholar Gabizon R, London N. A fast and clean BTK inhibitor. J Med Chem. 2020;63:5100–1. CAS PubMed PubMed Central Google Scholar Angst D, Gessier F, Janser P, Vulpe...
et al. Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. N. Engl. J. Med. 380, 2406–2417 (2019). Article CAS PubMed Google Scholar Reich, D. S. et al. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis...
19. Kuhle J, Kappos L, Mantalban X, et al.The effect of evobrutinib, a BTK Inhibitor, on blood neurofilament light chain levels in relapsing multiple sclerosis. Presented at: the American Academy of Neurology 2021 VIrtual Congress; April 17-22, 2021; Virtual. ...
An abnormally active metabolism in immune B-cells can trigger the release of pro-inflammatory signaling molecules that drive further inflammation in multiple sclerosis (MS), a study found. Selectively blocking certain metabolic processes with a Bruton’s tyrosine kinase (BTK) inhibitor normalized B-cel...
Methods for treating MS using pyrimidine and pyridine compounds with BTK inhibitory activityThe present invention provides methods of treating MS using pyrimidine and pyridine compounds which are inhibitors of Bruton's tyrosine kinase (BTK).DELLOVADE Tammy...
The French drugmaker will take full control of SAR442168, a BTK inhibitor developed for multiple sclerosis that it in-licensed from the California biotech company in 2017. ByAlaric DeArment BioPharma,Artificial Intelligence Roche, PicnicHealth start RWD partnership with multiple sclerosis focus ...